Benzinga | Mar 9, 2021 09:59AM EST

Citigroup Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $35

Citigroup analyst Neena Bitritto-Garg downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $66 to $35.